



 Patient Name
 : Mrs.P MANASA

 Age/Gender
 : 31 Y 10 M 14 D/F

 UHID/MR No
 : CHSR.0000153413

 Visit ID
 : CHSROPV288332

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275079

 Collected
 : 25/Nov/2023 08:15AM

 Received
 : 25/Nov/2023 11:30AM

 Reported
 : 25/Nov/2023 12:44PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

HAEMOGLOBIN	14.2	g/dL	12-15	Spectrophotometer
PCV	43.30	%	36-46	Electronic pulse & Calculation
RBC COUNT	5.76	Million/cu.mm	3.8-4.8	Electrical Impedence
MCV	75.2	fL	83-101	Calculated
MCH	24.7	pg	27-32	Calculated
MCHC	32.9	g/dL	31.5-34.5	Calculated
R.D.W	14.2	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	5,800	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT (D	DLC)			
NEUTROPHILS	47.2	%	40-80	Electrical Impedance
LYMPHOCYTES	42.2	%	20-40	Electrical Impedance
EOSINOPHILS	2.2	%	1-6	Electrical Impedance
MONOCYTES	8.1	%	2-10	Electrical Impedance
BASOPHILS	0.3	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	2737.6	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	2447.6	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	127.6	Cells/cu.mm	20-500	Calculated
MONOCYTES	469.8	Cells/cu.mm	200-1000	Calculated
BASOPHILS	17.4	Cells/cu.mm	0-100	Calculated
PLATELET COUNT	274000	cells/cu.mm	150000-410000	Electrical impedence
ERYTHROCYTE SEDIMENTATION RATE (ESR)	14	mm at the end of 1 hour	0-20	Modified Westegren method

RBCs: are normocytic normochromic

WBCs: are normal in total number with mild increase in lymphocytes.

PLATELETS: appear adequate in number.

HEMOPARASITES: negative

Page 1 of 14







: Mrs.P MANASA

Age/Gender

: 31 Y 10 M 14 D/F

UHID/MR No

: CHSR.0000153413

Visit ID Ref Doctor : CHSROPV288332

Emp/Auth/TPA ID

: Dr.SELF : 275079 Collected

: 25/Nov/2023 08:15AM

Received

: 25/Nov/2023 11:30AM

Reported Status : 25/Nov/2023 12:44PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - 2D ECHO - PAN INDÍA - FY2324

Test Name

Result

Unit

Bio. Ref. Range

Method

IMPRESSION: NORMOCYTIC NORMOCHROMIC BLOOD PICTURE.

Suggested Iron profile in view of reduced RBC indices and increased RBC count.

Kindly correlate clinically.

Page 2 of 14

SIN No:BED230289137

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







: Mrs.P MANASA

Age/Gender

: 31 Y 10 M 14 D/F

UHID/MR No

: CHSR.0000153413

Visit ID

: CHSROPV288332

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : 275079 Collected

: 25/Nov/2023 08:15AM

Received

: 25/Nov/2023 11:30AM

Reported Status : 25/Nov/2023 02:13PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - 2D ECHO - PAN INDÍA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
-----------	--------	------	-----------------	--------

BLOOD GROUP TYPE	0	Microplate
		Hemagglutination
Rh TYPE	Positive	Microplate
		Hemagglutination

Page 3 of 14

SIN No:BED230289137

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







: Mrs.P MANASA

Age/Gender

: 31 Y 10 M 14 D/F

UHID/MR No

: CHSR.0000153413

Visit ID Ref Doctor : CHSROPV288332 : Dr.SELF

Emp/Auth/TPA ID : 275079

Collected

: 25/Nov/2023 11:28AM

Received Reported : 25/Nov/2023 04:08PM

Status

: 25/Nov/2023 05:07PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
Test Name	Result	Unit	Bio. Ref. Range	Ме

GLUCOSE, FASTING, NAF PLASMA	84	mg/dL	70-100	HEXOKINASE
------------------------------	----	-------	--------	------------

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

GLUCOSE, POST PRANDIAL (PP), 2 HOURS, SODIUM FLUORIDE PLASMA (2	86	mg/dL	70-140	HEXOKINASE
HR)				

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Page 4 of 14

SIN No:PLF02059136,PLP1390150
NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE





Patient Name : Mrs.P MANASA Age/Gender : 31 Y 10 M 14 D/F

UHID/MR No : CHSR.0000153413 Visit ID : CHSROPV288332

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275079 Collected : 25/Nov/2023 08:15AM
Received : 25/Nov/2023 11:39AM
Reported : 25/Nov/2023 12:20PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
HBA1C, GLYCATED HEMOGLOBIN , WHOLE BLOOD EDTA	5.6	%		HPLC
ESTIMATED AVERAGE GLUCOSE (eAG) , WHOLE BLOOD EDTA	114	mg/dL		Calculated

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %	
NON DIABETIC	<5.7	
PREDIABETES	5.7 – 6.4	
DIABETES	≥ 6.5	
DIABETICS		
EXCELLENT CONTROL	6 – 7	F1
FAIR TO GOOD CONTROL	7 – 8	
UNSATISFACTORY CONTROL	8 – 10	
POOR CONTROL	>10	

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control
 - A: HbF >25%
 - B: Homozygous Hemoglobinopathy.
 - (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 5 of 14

SIN No:EDT230105880

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE





Emp/Auth/TPA ID



 Patient Name
 : Mrs.P MANASA

 Age/Gender
 : 31 Y 10 M 14 D/F

 UHID/MR No
 : CHSR.0000153413

 Visit ID
 : CHSROPV288332

: 275079

Ref Doctor : Dr.SELF

Collected : 25/Nov/2023 08:15AM
Received : 25/Nov/2023 12:21PM
Reported : 25/Nov/2023 01:33PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

L IPID PROFILE , SERUM				
TOTAL CHOLESTEROL	168	mg/dL	<200	CHO-POD
TRIGLYCERIDES	176	mg/dL	<150	GPO-POD
HDL CHOLESTEROL	45	mg/dL	40-60	Enzymatic Immunoinhibition
NON-HDL CHOLESTEROL	123	mg/dL	<130	Calculated
LDL CHOLESTEROL	87.7	mg/dL	<100	Calculated
VLDL CHOLESTEROL	35.2	mg/dL	<30	Calculated
CHOL / HDL RATIO	3.73		0-4.97	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
. D .	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60	*		
INON-HOLCHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- **4.** Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- **5.** As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6. VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 350mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.

Page 6 of 14

SIN No:SE04549652

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







: Mrs.P MANASA

Age/Gender

: 31 Y 10 M 14 D/F

UHID/MR No

: CHSR.0000153413

Visit ID

: CHSROPV288332

Ref Doctor Emp/Auth/TPA ID

: 275079

· Dr SELE

Collected

: 25/Nov/2023 08:15AM

Received

: 25/Nov/2023 12:21PM

Reported Status

: 25/Nov/2023 01:33PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - 2D ECHO - PAN INDIA - FY2324 **Test Name** Result Unit Bio. Ref. Range Method

IVER FUNCTION TEST (LFT) , SERUM				
BILIRUBIN, TOTAL	0.66	mg/dL	0.3-1.2	DPD
BILIRUBIN CONJUGATED (DIRECT)	0.11	mg/dL	<0.2	DPD
BILIRUBIN (INDIRECT)	0.55	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	30	U/L	<35	IFCC
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	26.0	U/L	<35	IFCC
ALKALINE PHOSPHATASE	72.00	U/L	30-120	IFCC
PROTEIN, TOTAL	7.48	g/dL	6.6-8.3	Biuret
ALBUMIN	4.60	g/dL	3.5-5.2	BROMO CRESOL GREEN
GLOBULIN	2.88	g/dĹ	2.0-3.5	Calculated
A/G RATIO	1.6		0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with
- · Disproportionate increase in AST, ALT compared with ALP.
- · Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- · Bilirubin may be elevated.
- ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.

3. Synthetic function impairment:

- Albumin- Liver disease reduces albumin levels.
- Correlation with PT (Prothrombin Time) helps.

Page 7 of 14





: Mrs.P MANASA

Age/Gender

: 31 Y 10 M 14 D/F

UHID/MR No Visit ID : CHSR.0000153413

Ref Doctor Emp/Auth/TPA ID : CHSROPV288332

: Dr.SELF : 275079 Collected

: 25/Nov/2023 08:15AM

Received

: 25/Nov/2023 12:21PM : 25/Nov/2023 01:33PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - 2D ECHO - PAN INDÍA - FY2324

Test Name

Result

Unit

Bio. Ref. Range

Method

Page 8 of 14



SIN No:SE04549652

 $NABL\ renewal\ accreditation\ under\ process$

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Apollo Health and Lifestyle Limited (CIN-U85110TG2000PLC115819)

Regd. Office: 1-10-60/62, Ashoka Raghupathi Chambers, 5th Floor, Begumpet, Hyderabad, Telangana - 500 016 | www.apollohl.com | Email ID: enquiry@apollohl.com, Ph No: 040-4904 7777, Fax No: 4904 7744

APOLLO CLINICS NETWORK







: Mrs.P MANASA

Age/Gender

: 31 Y 10 M 14 D/F

UHID/MR No

: CHSR.0000153413

Visit ID

: CHSROPV288332

: Dr.SELF

: 275079

Ref Doctor Emp/Auth/TPA ID Collected

: 25/Nov/2023 08:15AM

Received

: 25/Nov/2023 12:21PM : 25/Nov/2023 01:33PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT), SERUM				
CREATININE	0.60	mg/dL	0.72 – 1.18	JAFFE METHOD
UREA	10.50	mg/dL	17-43	GLDH, Kinetic Assay
BLOOD UREA NITROGEN	4.9	mg/dL	8.0 - 23.0	Calculated
URIC ACID	4.44	mg/dL	2.6-6.0	Uricase PAP
CALCIUM	9.30	mg/dL	8.8-10.6	Arsenazo III
PHOSPHORUS, INORGANIC	4.43	mg/dL	2.5-4.5	Phosphomolybdate Complex
SODIUM	136	mmol/L	136–146	ISE (Indirect)
POTASSIUM	4.6	mmol/L	3.5–5.1	ISE (Indirect)
CHLORIDE	100	mmol/L	101–109	ISE (Indirect)

Page 9 of 14



SIN No:SE04549652

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







: Mrs.P MANASA

Age/Gender

: 31 Y 10 M 14 D/F

UHID/MR No

: CHSR.0000153413

Visit ID

: CHSROPV288332

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275079 Collected : 25/Nov/2023 08:15AM Received : 25/Nov/2023 12:21PM

Reported : 25/Nov/2023 01:33PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - 2D ECHO - PAN INDÍA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
-----------	--------	------	-----------------	--------

GAMMA GLUTAMYL TRANSPEPTIDASE	21.00	U/L	<38	IFCC	
(GGT), SERUM					

Page 10 of 14



SIN No:SE04549652

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Apollo Health and Lifestyle Limited (CIN-U85110TG2000PLC115819)

Regd. Office: 1-10-60/62, Ashoka Raghupathi Chambers, 5th Floor, Begumpet, Hyderabad, Telangana - 500 016 | www.apollohl.com | Email ID: enquiry@apollohl.com, Ph No: 040-4904 7777, Fax No: 4904 7744

APOLLO CLINICS NETWORK







: Mrs.P MANASA

Age/Gender

: 31 Y 10 M 14 D/F

UHID/MR No

: CHSR.0000153413

Visit ID Ref Doctor : CHSROPV288332

: Dr.SELF

: 275079

Emp/Auth/TPA ID

Collected

: 25/Nov/2023 08:15AM

Received

: 25/Nov/2023 12:22PM

Reported Status : 25/Nov/2023 01:57PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method

THYROID PROFILE TOTAL (T3, T4, TSH), SERUM

······································				
TRI-IODOTHYRONINE (T3, TOTAL)	1.34	ng/mL	0.7-2.04	CLIA
THYROXINE (T4, TOTAL)	9.86	μg/dL	5.48-14.28	CLIA
THYROID STIMULATING HORMONE (TSH)	6.244	μIU/mL	0.34-5.60	CLIA

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 - 3.0

- 1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- 2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- 3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- 4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	T4	FT4	Conditions	
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis	
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.	
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism	
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy	
Low	N	N	N	abclinical Hyperthyroidism	
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism	
Low	N	High	High	Thyroiditis, Interfering Antibodies	
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes	
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma	

Page 11 of 14

SIN No:SPL23167278

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE





: Mrs.P MANASA

Age/Gender

: 31 Y 10 M 14 D/F

UHID/MR No Visit ID : CHSR.0000153413

Ref Doctor

: CHSROPV288332

Emp/Auth/TPA ID

: Dr.SELF : 275079 Collected

: 25/Nov/2023 08:15AM

Received

: 25/Nov/2023 05:05PM

Reported

: 25/Nov/2023 07:09PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

COMPLETE URINE EXAMINATION (C	UE) , URINE			
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
pH	7.5		5-7.5	DOUBLE INDICATOR
SP. GRAVITY	1.010		1.002-1.030	Bromothymol Blue
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	GLUCOSE OXIDASE
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING REACTION
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	SODIUM NITRO PRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	MODIFED EHRLICH REACTION
BLOOD	NEGATIVE		NEGATIVE	Peroxidase
NITRITE	NEGATIVE		NEGATIVE	Diazotization
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	LEUCOCYTE ESTERASE
CENTRIFUGED SEDIMENT WET MO	OUNT AND MICROSCOPY			
PUS CELLS	1-2	/hpf	0-5	Microscopy
EPITHELIAL CELLS	2-3	/hpf	<10	MICROSCOPY
RBC	NIL	/hpf	0-2	MICROSCOPY
CASTS	NIL		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

Page 12 of 14

SIN No:UR2226443

NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE







: Mrs.P MANASA

Age/Gender UHID/MR No : 31 Y 10 M 14 D/F : CHSR.0000153413

Visit ID

: CHSROPV288332

: Dr.SELF

: 275079

Ref Doctor Emp/Auth/TPA ID

URINE GLUCOSE(FASTING)

Collected : 25/Nov/2023 08:15AM Received : 25/Nov/2023 05:05PM : 25/Nov/2023 05:56PM

Reported

Status

: Final Report

NEGATIVE

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

Dipstick

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - 2D ECHO - PAN INDIA - FY2324					
Test Name	Result	Unit	Bio. Ref. Range	Method	
URINE GLUCOSE(POST PRANDIAL)	NEGATIVE		NEGATIVE	Dipstick	

NEGATIVE

Page 13 of 14



SIN No:UPP015826,UF009827 NABL renewal accreditation under process

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE











: Mrs.P MANASA

Age/Gender

: 31 Y 10 M 14 D/F

UHID/MR No

: CHSR.0000153413

Visit ID

: CHSROPV288332

Ref Doctor Emp/Auth/TPA ID

: Dr.SELF : 275079 Collected

: 25/Nov/2023 01:27PM

Received

: 26/Nov/2023 04:20PM

Reported

: 27/Nov/2023 07:44PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CYTOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - 2D ECHO - PAN INDIA - FY2324

	CYTOLOGY NO.	19757/23
I	SPECIMEN	
a	SPECIMEN ADEQUACY	ADEQUATE
b	SPECIMEN TYPE	LIQUID-BASED PREPARATION (LBC)
	SPECIMEN NATURE/SOURCE	CERVICAL SMEAR
c	ENDOCERVICAL-TRANSFORMATION ZONE	PRESENT WITH ENDOCERVICAL CELLS
d	COMMENTS	SATISFACTORY FOR EVALUATION
II	MICROSCOPY	Superficial and intermediate squamous epithelial cells with benign morphology.
		Negative for intraepithelial lesion/ malignancy.
Ш	RESULT	
a	EPITHEIAL CELL	
	SQUAMOUS CELL ABNORMALITIES	NOT SEEN
	GLANDULAR CELL ABNORMALITIES	NOT SEEN
b	ORGANISM	NIL
IV	INTERPRETATION	NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY

Pap Test is a screening test for cervical cancer with inherent false negative results. Regular screening and follow-up is recommended (Bethesda-TBS-2014) revised

*** End Of Report ***

Result/s to Follow: PERIPHERAL SMEAR

DR. K. RAMA KRISHNA REDDY M.B.B.S. M.D

CONSULTANT PATHOLOGIST

DR.SHIVARAJA SHETTY
M.B.B.S,M.D(Biochemistry)
CONSULTANT BIOCHEMIST

Dr.Shobha Emmanuel M.B.B.S,M.D(Pathology) Consultant Pathologist Dr. Chinki Anupam M.B.B.S,M.D(Pathology) Consultant Pathologist

Page 14 of 14

SIN No:CS070542

This test has been performed at Apollo Health & Lifestyle Ltd, Global Reference Laboratory, Hyderabad

THIS TEST HAS BEEN PERFORMED AT APOLLO HEALTH AND LIFSTYLE LIMITED- RRL BANGALORE

Apollo Health and Lifestyle Limited (CIN-U85110TG2000PLC115819)

 $Regd. Office: 1-10-60/62, A shoka Raghupathi Chambers, 5 th Floor, Begumpet, Hyderabad, Telangana - 500\,016 \,|\, www.apollohl.com \,|\, Email ID: enquiry@apollohl.com, Ph No: 040-4904\,7777, Fax No: 4904\,7744$





Name : Mrs. P MANASA

Age: 31 Y

Sex: F

Address: HSR

Plan

: ARCOFEMI MEDIWHEEL FEMALE AHC CREDIT PAN


INDIA OP AGREEMENT

UHID:CHSR.0000153413

OP Number: CHSROPV288332

Bill No: CHSR-OCR-63975 Date : 25.11.2023 08:10

no	Serive Type/ServiceName	Department
1	ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - F	
	UNINE GLUCOSE(FASTING)	
1	GAMMA GLUTAMYL TRANFERASE (GGT)	•
3	SONO MAMOGRAPHY - SCREENING	
	HISA IC GLYCATED HEMOGLOBIN	
- 5	DECHO VO	
A	LIVER FUNCTION TEST (LFT)	
	X-RAY CHEST PA (3	
٤	GLUCOSE, FASTING	
وي _	HEMOGRAM + PERIPHERAL SMEAR	
10	ENT CONSULTATION	
11	FITNESS BY GENERAL PHYSICIAN	
12	GYNAECOLOGY CONSULTATION / 5	
13	DIET CONSULTATION	
	COMPLETE URINE EXAMINATION	
	URINE GLUCOSE(POST PRANDIAL)	
	PERIPHERAL SMEAR	
_	BEG 9-1	
	BLOOD GROUP ABO AND RH FACTOR	
70	LIPID PROFILE	
20	BODY MASS INDEX (BMI)	
21	LBC PAP TEST- PAPSURE 5	
22	OPTHAL BY GENERAL PHYSICIAN	
23	RENAL PROFILE/RENAL FUNCTION TEST (RFT/KFT)	
-	ULTRASOUND - WHOLE ABDOMEN (4	
25	THYROID PROFILE (TOTAL T3, TOTAL T4, TSH)	
	DENTAL CONSULTATION	
7/22	GLUCOSE, POST PRANDIAL (PP), 2 HOURS (POST MEAL)	







Mrs. Klanason 3 ly / Fernall 2 r/11/23

BC8F9FPP8F-N9

Height:	Weight:	BMI :	Waist Circum :
Temp :	Pulse :	Resp:	B.P :

General Examination / Allergies History

Pt vas 10mm for regular clental much up. Clinical Diagnosis & Management Plan

0/6.

Pt was ald PCT treated too ty

7.] which new grattured

calcules + + stains + .

Follow up date:

Dector Signature





Date

25-11-2023

Department

: GENERAL

MR NO

: CHSR.0000153413

Doctor

Name

: Mrs. P MANASA

Registration No

Age/ Gender

31 Y / Female

Qualification

Consultation Timing:

08:10

Weight:

BMI:

Waist Circum:

Height: Temp:

Pulse:

Resp:

B.P:

General Examination / Allergies

History

Clinical Diagnosis & Management Plan

Olt: - MA-AUY
PILY Brees

AD-DUY

MIT: Regular youle.

MIT: Regular of Long 10/1/83

30-32 day of Long 10/1/83

Breast D

Breast D

RBC PUP Garcer)

Follow up date:

Doctor Signature





Date

25-11-2023

Department

GENERAL

MR NO

: CHSR.0000153413

Doctor

.

Name

: Mrs. P MANASA

Registration No

616 without 616
w16
colour rission

Qualification

Age/ Gender

31 Y / Female

Consultation Timing: 08:10

 Height:
 153
 Weight:
 69 kg
 BMI:
 Waist Circum:

 Temp:
 Pulse:
 74
 Resp:
 B.P: 106/79


General Examination / Allergies

History

Clinical Diagnosis & Management Plan

Follow up date:

Doctor Signature



नाम P.MANASA Name

कर्म बारी कूट क्र 115326 E.C. No.

जारीकर्ता प्राधिकारी Issuing Authority



धारिक का हस्ताधर Signature of Holder



Patient Name : Mrs. P MANASA Age/Gender : 31 Y/F

UHID/MR No. : CHSR.0000153413 **OP Visit No** : CHSROPV288332

 Sample Collected on
 : 26-11-2023 10:23

 LRN#
 : RAD2159381
 Specimen
 : 26-11-2023 10:23

Ref Doctor : SELF

DEPARTMENT OF RADIOLOGY

X-RAY CHEST PA

Bilateral lung fields appear normal.

: 275079

Emp/Auth/TPA ID

Cardiac size and shape are normal.

No mediastinal pathology is seen.

Both hila are normal in size and density.

Both CP angles are normal.

Both domes of diaphragm are normal.

IMPRESSION: NORMAL STUDY.

(The findings should always be considered in correlation with the clinical and other investigation finding where applicable.) It is only a professional opinion, Not valid for medico legal purpose.

Dr. VIGNESH K

MBBS, MD Radio-Diagnosis

Radiology



Patient Name : Mrs. P MANASA Age/Gender : 31 Y/F

UHID/MR No. : CHSR.0000153413 **OP Visit No** : CHSROPV288332

 Sample Collected on
 : 25-11-2023 12:04

 LRN#
 : RAD2159381
 Specimen
 : 25-11-2023 12:04

Ref Doctor : SELF

DEPARTMENT OF RADIOLOGY

SONO MAMOGRAPHY - SCREENING

Both breast parenchymal echotexture appear normal.

: 275079

No ductal dilatation was noted.

No focal lesion was noted.

Emp/Auth/TPA ID

Nipples and subaerolar region appear normal.

Skin and subcutaneous tissue is normal.

No axillary lymphadenopathy was appreciated.

IMPRESSION:

- NORMAL STUDY.
- BI-RADS CLASSIFICATIONS:Category 1: Negative

(The sonography findings should always be considered in correlation with the clinical and other investigation finding where applicable.) It is only a professional opinion, Not valid for medico legal purpose.

Dr. M SONIA PAVANI
MBBS, M.D (Radio-Diagnosis)
Radiology



: CHSROPV288332

: 25-11-2023 09:01

Patient Name : Mrs. P MANASA Age/Gender : 31 Y/F

UHID/MR No.

: CHSR.0000153413

Sample Collected on

LRN#

: RAD2159381

Ref Doctor : SELF **Emp/Auth/TPA ID** : 275079

OP Visit No

Reported on

Specimen

DEPARTMENT OF RADIOLOGY

ULTRASOUND - WHOLE ABDOMEN

LIVER: Normal in size(15.6 cm) and echotexture. No intra hepatic biliary / venous radicular dilation. No focal lesion seen. CBD and Main Portal vein appear normal.

GALL BLADDER: Well distended. Normal in internal contents. Wall Thickness is normal. multipe caluli (10 to 15) noted largest measuring 8 mm

SPLEEN: Normal in size and echotexture. No focal lesion is seen. No evidence of splenic hilar varices/collaterals.

PANCREAS: Only head and body visualized, appear normal.

KIDNEYS: Both kidneys are normal in size, shape and outlines Cortico medullary delineation is normal. No Hydronephrosis / No calculi.

URINARY BLADDER: Well distended. Normal in internal contents. Wall thickness is normal.

UTERUS: Normal in size and echotexture. It measures cm. Uniform myometrial echoes are normal. Endometrial thickness is normal and measures 8.6 mm.

OVARIES: Both ovaries are normal in size and echotexture.

Right ovary measures Vol: 28 cc. Left ovary measures Vol: 15 cc.

Both ovaries are enlarged in size with multiple peripherally arranged follicles with central echogenic stroma.

No free fluid is seen in the peritoneum.

IMPRESSION

- Cholelithiasis
- Polycystic pattern of Ovaries as described.

(The sonography findings should always be considered in correlation with the clinical and other investigation finding where applicable.) It is only a professional opinion, Not valid for medico legal purpose.

Dr. VIGNESH K
MBBS, MD Radio-Diagnosis
Radiology

Mrs. P MANASA
Age/Gender: 31 Y/F
Address: HSR
Location: MR No: CHSR.0000153413 CHSROPV288332 Visit ID:

Visit Date: 25-11-2023 08:10

BANGALORE, KARNATAKA Discharge Date:

Doctor: Referred By: SELF Department: GENERAL
Rate Plan: HSR LAYOUT_06042023
Spansor: APCOFFM_HEALTHCAL

ARCOFEMI HEALTHCARE LIMITED Sponsor:

Consulting Doctor: Dr. KAVYA J

HT-CHIEF COMPLAINTS AND PRESENT KNOWN ILLNESS

SYSTEMIC REVIEW

HT-HISTORY

PHYSICAL EXAMINATION

SYSTEMIC EXAMINATION

IMPRESSION

RECOMMENDATION

Doctor's Signature

Name: Mrs. P MANASA

Age/Gender: 31 Y/F Address: HSR

Location: BANGALORE, KARNATAKA

Doctor:

Department: GENERAL

Rate Plan: HSR LAYOUT_06042023

Sponsor: ARCOFEMI HEALTHCARE LIMITED

Consulting Doctor: Dr. MRIDULA V AMARNATH

Doctor's Signature

MR No: CHSR.0000153413
Visit ID: CHSROPV288332
Visit Date: 25-11-2023 08:10

Discharge Date:

Referred By: SELF

MR No: Visit ID:

Mrs. P MANASA
Age/Gender: 31 Y/F
Address: HSR
Location: CHSROPV288332 Visit Date: 25-11-2023 08:10

CHSR.0000153413

BANGALORE, KARNATAKA Discharge Date:

Doctor: Referred By: SELF

Department: GENERAL
Rate Plan: HSR LAYOUT_06042023
Spansor: APCOFFM_HEALTHCAL

ARCOFEMI HEALTHCARE LIMITED Sponsor: Consulting Doctor: Dr. ARPITA SUBHASH

HT-CHIEF COMPLAINTS AND PRESENT KNOWN ILLNESS

SYSTEMIC REVIEW

HT-HISTORY

PHYSICAL EXAMINATION

SYSTEMIC EXAMINATION

IMPRESSION

RECOMMENDATION

Doctor's Signature

Name: Mrs. P MANASA

Age/Gender: 31 Y/F Address: HSR

Location: BANGALORE, KARNATAKA

Doctor:

Department: GENERAL

Rate Plan: HSR LAYOUT_06042023

Sponsor: ARCOFEMI HEALTHCARE LIMITED

Consulting Doctor: Dr. KARISHMA PATEL

Doctor's Signature

MR No: CHSR.0000153413
Visit ID: CHSROPV288332
Visit Date: 25-11-2023 08:10

Discharge Date:

Referred By: SELF

Mrs. P MANASA
Age/Gender: 31 Y/F
Address: HSR
Location: MR No: Visit ID:

CHSROPV288332 Visit Date: 25-11-2023 08:10

CHSR.0000153413

BANGALORE, KARNATAKA Discharge Date: Doctor: Referred By: SELF

Department: GENERAL
Rate Plan: HSR LAYOUT_06042023
Sponsor: ARCOFEMI HEALTHCAL

ARCOFEMI HEALTHCARE LIMITED Sponsor: Consulting Doctor: Dr. VANITA VAISHNAV

HT-CHIEF COMPLAINTS AND PRESENT KNOWN ILLNESS

SYSTEMIC REVIEW

HT-HISTORY

PHYSICAL EXAMINATION

SYSTEMIC EXAMINATION

IMPRESSION

RECOMMENDATION

Doctor's Signature

II)afe	Pulse (Beats/min)	_	Resp (Rate/min)	Temp (F)	Height (cms)	Weight	Percentage	Fat Level	Body Age (Years)	BMI	Circum	Hip (cms)	(cms)	Waist & Hip Ratio	User
25-11-2023 17:47	-			_	153 cms	69 Kgs	%	%	Years	29.48	cms	cms	cms		AHLL10116

II)afe	Pulse (Beats/min)	_	Resp (Rate/min)	Temp (F)	Height (cms)	Weight	Percentage	Fat Level	Body Age (Years)	BMI	Circum	Hip (cms)	(cms)	Waist & Hip Ratio	User
25-11-2023 17:47	-			_	153 cms	69 Kgs	%	%	Years	29.48	cms	cms	cms		AHLL10116

II)afe	Pulse (Beats/min)	_	Resp (Rate/min)	Temp (F)	Height (cms)	Weight	Percentage	Fat Level	Body Age (Years)	BMI	Circum	Hip (cms)	(cms)	Waist & Hip Ratio	User
25-11-2023 17:47	-			_	153 cms	69 Kgs	%	%	Years	29.48	cms	cms	cms		AHLL10116

II)afe	Pulse (Beats/min)	_	Resp (Rate/min)	Temp (F)	Height (cms)	Weight	Percentage	Fat Level	Body Age (Years)	BMI	Circum	Hip (cms)	(cms)	Waist & Hip Ratio	User
25-11-2023 17:47	-			_	153 cms	69 Kgs	%	%	Years	29.48	cms	cms	cms		AHLL10116

II)afe	Pulse (Beats/min)	_	Resp (Rate/min)	Temp (F)	Height (cms)	Weight	Percentage	Fat Level	Body Age (Years)	BMI	Circum	Hip (cms)	(cms)	Waist & Hip Ratio	User
25-11-2023 17:47	-			_	153 cms	69 Kgs	%	%	Years	29.48	cms	cms	cms		AHLL10116

Patient Name : Mrs. P MANASA Age : 31 Y/F

UHID : CHSR.0000153413 OP Visit No : CHSROPV288332

Conducted By: : Conducted Date : 25-11-2023 18:15

Referred By : SELF

• :2D Echo Cardiography

• Chambers

• Left Ventricle :Normal in size, NO RWMA at Rest

Left Atrium : NormalRight Ventricle : NormalRight Atrium : Normal

• Septa

IVS: Intact

• IAS: Intact

Valves

• Mitral Valve: Normal.

Tricuspid Valve: Normal, Trace TR, No PAHAortic Valve: Tricuspid, Normal mobility

• Pulmonary Valve : Normal

Great Valves

• Aorta : Normal

• Pulmonary Artery: Normal

Patient Name : Mrs. P MANASA Age : 31 Y/F

 UHID
 : CHSR.0000153413
 OP Visit No
 : CHSROPV288332

 Conducted By:
 :
 Conducted Date
 : 25-11-2023 18:15

Referred By : SELF

Pericardium : Normal

Doppler Echocardiograph

Mitral Valve	E	0.83	m/sec	<u>A</u>	0.6	m/sec	e/a 1.39
--------------	---	------	-------	----------	-----	-------	----------

Aortic Valve Vmax 1.26 m/sec PG 6.4 mm

Distolic Dysfunction None

M – Mode Measurement

Parameter	Observed Valve	Normal Range	
Aorta	25	26- 36	mm
Left Atrium	26	27-38	mm
IVS- Diastole	11	09-11	mm
Left Ventricle –Diastole	44	42-59	mm
Posterior wall-Diastole	11	09-11	mm
IVS-Systole	15	13-15	mm
Left Ventricle- Systole	26	21-40	mm
Posterior wall- Systole	15	13-15	mm
Ejection Fraction	60%	->50	%

IMPRESSION

• NORMAL SIZED CARDIAC VALVES AND CHAMBERS

Patient Name : Mrs. P MANASA Age : 31 Y/F

 UHID
 : CHSR.0000153413
 OP Visit No
 : CHSROPV288332

 Conducted By:
 :
 Conducted Date
 : 25-11-2023 18:15

Referred By : SELF

• NO RWMA'S AT REST

- NORMAL LV & RV SYSTOLIC FUNCTION LVEF 60%
- NORMAL LV DIASTOLIC FUNCTION
- NO PERICARDIAL EFFUSION / VEGETATION / CLOT.

Dr RAMNARESH SOUDRI MD, DM (CARDIOLOGY), FSCAI Consultant Interventional Cardiologist

Ref Doctor : Dr.SELF

Emp/Auth/TPA ID : 275079

Collected : 25/Nov/2023 08:15AM
Received : 25/Nov/2023 11:30AM
Reported : 25/Nov/2023 12:44PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

HAEMOGLOBIN	14.2	g/dL	12-15	Spectrophotometer
PCV	43.30	%	36-46	Electronic pulse & Calculation
RBC COUNT	5.76	Million/cu.mm	3.8-4.8	Electrical Impedence
MCV	75.2	fL	83-101	Calculated
MCH	24.7	pg	27-32	Calculated
MCHC	32.9	g/dL	31.5-34.5	Calculated
R.D.W	14.2	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	5,800	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT (E	DLC)			
NEUTROPHILS	47.2	%	40-80	Electrical Impedance
LYMPHOCYTES	42.2	%	20-40	Electrical Impedance
EOSINOPHILS	2.2	%	1-6	Electrical Impedance
MONOCYTES	8.1	%	2-10	Electrical Impedance
BASOPHILS	0.3	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	2737.6	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	2447.6	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	127.6	Cells/cu.mm	20-500	Calculated
MONOCYTES	469.8	Cells/cu.mm	200-1000	Calculated
BASOPHILS	17.4	Cells/cu.mm	0-100	Calculated
PLATELET COUNT	274000	cells/cu.mm	150000-410000	Electrical impedend
ERYTHROCYTE SEDIMENTATION RATE (ESR)	14	mm at the end of 1 hour	0-20	Modified Westegrei method

RBCs: are normocytic normochromic

WBCs: are normal in total number with mild increase in lymphocytes.

PLATELETS: appear adequate in number.

HEMOPARASITES: negative

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275079 Collected : 25/Nov/2023 08:15AM
Received : 25/Nov/2023 11:30AM
Reported : 25/Nov/2023 12:44PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

IMPRESSION: NORMOCYTIC NORMOCHROMIC BLOOD PICTURE.

Suggested Iron profile in view of reduced RBC indices and increased RBC count.

Kindly correlate clinically.



Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275079 Collected : 25/Nov/2023 08:15AM
Received : 25/Nov/2023 11:30AM
Reported : 25/Nov/2023 02:13PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY	ANNUAL PLUS CHE	CK ADVANCED	- FEMALE - 2D ECHO -	PAN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

BLOOD GROUP ABO AND RH FACTOR, WHOLE BLOOD EDTA					
BLOOD GROUP TYPE	0	Microplate Hemagglutination			
Rh TYPE	Positive	Microplate Hemagglutination			



Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275079 Collected : 25/Nov/2023 11:28AM
Received : 25/Nov/2023 04:08PM
Reported : 25/Nov/2023 05:07PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

GLUCOSE, FASTING, NAF PLASMA	84	mg/dL	70-100	HEXOKINASE	
------------------------------	----	-------	--------	------------	--

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

GLUCOSE, POST PRANDIAL (PP), 2 HOURS, SODIUM FLUORIDE PLASMA (2	86	mg/dL	70-140	HEXOKINASE
HR)				

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.



Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275079 Collected : 25/Nov/2023 08:15AM
Received : 25/Nov/2023 11:39AM
Reported : 25/Nov/2023 12:20PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
UDA40 OLVOATED HEMOOLODIN	5.0	0/		LIDLO
HBA1C, GLYCATED HEMOGLOBIN , WHOLE BLOOD EDTA	5.6	%		HPLC
ESTIMATED AVERAGE GLUCOSE (eAG) , WHOLE BLOOD EDTA	114	mg/dL		Calculated

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 – 6.4
DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 – 8
UNSATISFACTORY CONTROL	8 – 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control
 - A: HbF >25%
 - B: Homozygous Hemoglobinopathy.
 - (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)



Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275079 Collected : 25/Nov/2023 08:15AM
Received : 25/Nov/2023 12:21PM
Reported : 25/Nov/2023 01:33PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

LIPID PROFILE , SERUM				
TOTAL CHOLESTEROL	168	mg/dL	<200	CHO-POD
TRIGLYCERIDES	176	mg/dL	<150	GPO-POD
HDL CHOLESTEROL	45	mg/dL	40-60	Enzymatic Immunoinhibition
NON-HDL CHOLESTEROL	123	mg/dL	<130	Calculated
LDL CHOLESTEROL	87.7	mg/dL	<100	Calculated
VLDL CHOLESTEROL	35.2	mg/dL	<30	Calculated
CHOL / HDL RATIO	3.73		0-4.97	Calculated

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
III .IDI .	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
INON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

- 1. Measurements in the same patient on different days can show physiological and analytical variations.
- 2. NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3. Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.
- **4.** Low HDL levels are associated with Coronary Heart Disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- **5.** As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6. VLDL, LDL Cholesterol Non HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 350mg/dl. When Triglycerides are more than 350 mg/dl LDL cholesterol is a direct measurement.



Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275079

 Collected
 : 25/Nov/2023 08:15AM

 Received
 : 25/Nov/2023 12:21PM

 Reported
 : 25/Nov/2023 01:33PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

LIVER FUNCTION TEST (LFT), SERUM				
BILIRUBIN, TOTAL	0.66	mg/dL	0.3–1.2	DPD
BILIRUBIN CONJUGATED (DIRECT)	0.11	mg/dL	<0.2	DPD
BILIRUBIN (INDIRECT)	0.55	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	30	U/L	<35	IFCC
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	26.0	U/L	<35	IFCC
ALKALINE PHOSPHATASE	72.00	U/L	30-120	IFCC
PROTEIN, TOTAL	7.48	g/dL	6.6-8.3	Biuret
ALBUMIN	4.60	g/dL	3.5-5.2	BROMO CRESOL GREEN
GLOBULIN	2.88	g/dL	2.0-3.5	Calculated
A/G RATIO	1.6		0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI
- Disproportionate increase in AST, ALT compared with ALP.
- Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- Bilirubin may be elevated.
- ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.

3. Synthetic function impairment:

- Albumin- Liver disease reduces albumin levels.
- Correlation with PT (Prothrombin Time) helps.

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275079 Collected : 25/Nov/2023 08:15AM
Received : 25/Nov/2023 12:21PM
Reported : 25/Nov/2023 01:33PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY	ANNUAL PLUS CHE	CK ADVANCED	- FEMALE - 2D ECHO	- PAN INDIA - FY2324

Test Name Result Unit Bio. Ref. Range Method



Patient Name : Mrs.P MANASA Age/Gender : 31 Y 10 M 14 D/F UHID/MR No : CHSR.0000153413 Visit ID : CHSROPV288332

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275079

Collected : 25/Nov/2023 08:15AM Received : 25/Nov/2023 12:21PM Reported : 25/Nov/2023 01:33PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY	ANNUAL PLUS CHE	CK ADVANCED	- FEMALE - 2D ECHO -	PAN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT) , SERUM					
CREATININE	0.60	mg/dL	0.72 – 1.18	JAFFE METHOD	
UREA	10.50	mg/dL	17-43	GLDH, Kinetic Assay	
BLOOD UREA NITROGEN	4.9	mg/dL	8.0 - 23.0	Calculated	
URIC ACID	4.44	mg/dL	2.6-6.0	Uricase PAP	
CALCIUM	9.30	mg/dL	8.8-10.6	Arsenazo III	
PHOSPHORUS, INORGANIC	4.43	mg/dL	2.5-4.5	Phosphomolybdate Complex	
SODIUM	136	mmol/L	136–146	ISE (Indirect)	
POTASSIUM	4.6	mmol/L	3.5-5.1	ISE (Indirect)	
CHLORIDE	100	mmol/L	101–109	ISE (Indirect)	



Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275079 Collected : 25/Nov/2023 08:15AM
Received : 25/Nov/2023 12:21PM
Reported : 25/Nov/2023 01:33PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY	ANNUAL PLUS CHE	CK ADVANCED	- FEMALE - 2D ECHO -	PAN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

GAMMA GLUTAMYL TRANSPEPTIDASE	21.00	U/L	<38	IFCC
(GGT), SERUM				



Patient Name : Mrs.P MANASA
Age/Gender : 31 Y 10 M 14 D/F
UHID/MR No : CHSR.0000153413

Visit ID : CHSROPV288332

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275079 Collected : 25/Nov/2023 08:15AM
Received : 25/Nov/2023 12:22PM
Reported : 25/Nov/2023 01:57PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - 2D ECHO - PAN INDIA - FY2324 Test Name Result Unit Bio. Ref. Range Method

THYROID PROFILE TOTAL (T3, T4, TSH), SERUM						
TRI-IODOTHYRONINE (T3, TOTAL)	1.34	ng/mL	0.7-2.04	CLIA		
THYROXINE (T4, TOTAL)	9.86	μg/dL	5.48-14.28	CLIA		
THYROID STIMULATING HORMONE (TSH)	6.244	μIU/mL	0.34-5.60	CLIA		

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)		
First trimester	0.1 - 2.5		
Second trimester	0.2 - 3.0		
Third trimester	0.3 – 3.0		

- 1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- **2.** TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- **3.** Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- 4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	T4	FT4	Conditions	
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis	
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.	
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism	
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy	
Low	N	N	N	Subclinical Hyperthyroidism	
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism	
Low	N	High	High	Thyroiditis, Interfering Antibodies	
N/Low	High	N	N	'3 Thyrotoxicosis, Non thyroidal causes	
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma	



Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275079 Collected : 25/Nov/2023 08:15AM
Received : 25/Nov/2023 05:05PM
Reported : 25/Nov/2023 07:09PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY	ANNUAL PLUS CHE	CK ADVANCED	- FEMALE - 2D ECHO -	- PAN INDIA - FY2324
Test Name	Result	Unit	Bio. Ref. Range	Method

COMPLETE URINE EXAMINATION (CUE) , URINE					
PHYSICAL EXAMINATION					
COLOUR	PALE YELLOW	PALE YELLOW		Visual	
TRANSPARENCY	CLEAR		CLEAR	Visual	
pH	7.5		5-7.5	DOUBLE INDICATOR	
SP. GRAVITY	1.010		1.002-1.030	Bromothymol Blue	
BIOCHEMICAL EXAMINATION					
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR	
GLUCOSE	NEGATIVE		NEGATIVE	GLUCOSE OXIDASE	
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING REACTION	
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	SODIUM NITRO PRUSSIDE	
UROBILINOGEN	NORMAL		NORMAL	MODIFED EHRLICH REACTION	
BLOOD	NEGATIVE		NEGATIVE	Peroxidase	
NITRITE	NEGATIVE		NEGATIVE	Diazotization	
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	LEUCOCYTE ESTERASE	
CENTRIFUGED SEDIMENT WET MOUN	IT AND MICROSCOPY	,			
PUS CELLS	1-2	/hpf	0-5	Microscopy	
EPITHELIAL CELLS	2-3	/hpf	<10	MICROSCOPY	
RBC	NIL	/hpf	0-2	MICROSCOPY	
CASTS	NIL		0-2 Hyaline Cast	MICROSCOPY	
CRYSTALS	ABSENT		ABSENT	MICROSCOPY	



Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275079 Collected : 25/Nov/2023 08:15AM
Received : 25/Nov/2023 05:05PM
Reported : 25/Nov/2023 05:56PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY							
ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - 2D ECHO - PAN INDIA - FY2324							
Test Name	Result	Unit	Bio. Ref. Range	Method			
URINE GLUCOSE(POST PRANDIAL)	NEGATIVE		NEGATIVE	Dipstick			
URINE GLUCOSE(FASTING)	NEGATIVE		NEGATIVE	Dipstick			







Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 275079 Collected : 25/Nov/2023 01:27PM
Received : 26/Nov/2023 04:20PM
Reported : 27/Nov/2023 07:44PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CYTOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - 2D ECHO - PAN INDIA - FY2324

LBC PA	BC PAP TEST (PAPSURE) , CERVICAL BRUSH SAMPLE				
	CYTOLOGY NO.	19757/23			
I	SPECIMEN				
a	SPECIMEN ADEQUACY	ADEQUATE			
b	SPECIMEN TYPE	LIQUID-BASED PREPARATION (LBC)			
	SPECIMEN NATURE/SOURCE	CERVICAL SMEAR			
c	ENDOCERVICAL-TRANSFORMATION ZONE	PRESENT WITH ENDOCERVICAL CELLS			
d	COMMENTS	SATISFACTORY FOR EVALUATION			
II	MICROSCOPY	Superficial and intermediate squamous epithelial cells with benign morphology. Negative for intraepithelial lesion/ malignancy.			
III	RESULT				
a	EPITHEIAL CELL				
	SQUAMOUS CELL ABNORMALITIES	NOT SEEN			
	GLANDULAR CELL ABNORMALITIES	NOT SEEN			
b	ORGANISM	NIL			
IV	INTERPRETATION	NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY			

Pap Test is a screening test for cervical cancer with inherent false negative results. Regular screening and follow-up is recommended (Bethesda-TBS-2014) revised

*** End Of Report ***

Result/s to Follow: PERIPHERAL SMEAR

DR. K. RAMA KRISHNA REDDY M.B.B.S. M.D

CONSULTANT PATHOLOGIST

DR.SHIVARAJA SHETTY
M.B.B.S,M.D(Biochemistry)
CONSULTANT BIOCHEMIST

Dr.Shobha Emmanuel M.B.B.S,M.D(Pathology) Consultant Pathologist Dr. Chinki Anupam M.B.B.S,M.D(Pathology) Consultant Pathologist

Page 14 of 14

